{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:51:20Z","timestamp":1761929480445},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.canlet.2010.02.020","type":"journal-article","created":{"date-parts":[[2010,3,23]],"date-time":"2010-03-23T06:41:12Z","timestamp":1269326472000},"page":"124-133","source":"Crossref","is-referenced-by-count":28,"title":["A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice"],"prefix":"10.1016","volume":"295","author":[{"given":"Genshen","family":"Zhong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiujun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfang","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongsu","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2010.02.020_bib1","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.tibtech.2007.05.001","article-title":"Engineering antibodies for clinical applications","volume":"25","author":"Jain","year":"2007","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.canlet.2010.02.020_bib2","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.drudis.2008.06.017","article-title":"Targeted therapy of cancer using diphtheria toxin-derived immunotoxins","volume":"13","author":"Potala","year":"2008","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.canlet.2010.02.020_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3322\/canjclin.56.4.226","article-title":"Targeted therapy of cancer: new prospects for antibodies and immunoconjugates","volume":"56","author":"Sharkey","year":"2006","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2010.02.020_bib4","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1038\/nbt1141","article-title":"Arming antibodies: prospects and challenges for immunoconjugates","volume":"23","author":"Wu","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2010.02.020_bib5","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/187152008783497055","article-title":"Enediyne anticancer antibiotic lidamycin: chemistry, biology and pharmacology","volume":"8","author":"Shao","year":"2008","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.canlet.2010.02.020_bib7","first-page":"336","article-title":"Relationship between the molecular composition of C1027, a new macromolecular antibiotic with enediyne chromophore, and its antitumor activity","volume":"30","author":"Shao","year":"1995","journal-title":"Acta Pharmcol. Sin."},{"key":"10.1016\/j.canlet.2010.02.020_bib8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2174\/1874467210801010050","article-title":"Pharmacology and therapeutic applications of enediyne antitumor antibiotics","volume":"1","author":"Shao","year":"2008","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.canlet.2010.02.020_bib9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1158\/0008-5472.CAN-08-2753","article-title":"C-1027, a radiomimetic enediyne anticancer drug, preferentially targets hypoxic cells","volume":"69","author":"Beerman","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib10","first-page":"984","article-title":"Characterization of novel multifunctional proteins involved in assembly of the enediyne natural products C-1027 and calicheamicin furthers the potential of combinatorial biosynthesis","volume":"20","author":"David","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2010.02.020_bib11","first-page":"37","article-title":"Gelatinase-mediated migration and invasion of cancer cells","volume":"1755","author":"Bjorklund","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.canlet.2010.02.020_bib12","first-page":"3113","article-title":"Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma","volume":"7","author":"Kallakury","year":"2001","journal-title":"Clin. Cancer. Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib13","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.humpath.2007.03.018","article-title":"Matrix metalloproteinase-9 activity is associated with poor prognosis in T3-T4 node-negative colorectal cancer","volume":"38","author":"Cho","year":"2007","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2010.02.020_bib14","first-page":"5224","article-title":"Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation","volume":"63","author":"Belotti","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccr.2007.11.032","article-title":"Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells","volume":"13","author":"Ahn","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2010.02.020_bib16","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.3748\/wjg.v11.i29.4478","article-title":"Antitumor activity of anti-type IV collagenase monoclonal antibody and its lidamycin conjugate against colon carcinoma","volume":"11","author":"Li","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.canlet.2010.02.020_bib17","first-page":"515","article-title":"Antitumor effects of the immunoconjugates composed of lidamycin and monoclonal antibody 3G11","volume":"38","author":"Wang","year":"2003","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.canlet.2010.02.020_bib18","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nbt1142","article-title":"Engineered antibody fragments and the rise of single domains","volume":"23","author":"Holliger","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2010.02.020_bib19","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/PPO.0b013e31817b07ae","article-title":"Antibodies for molecular imaging of cancer","volume":"14","author":"Wu","year":"2008","journal-title":"Cancer J."},{"key":"10.1016\/j.canlet.2010.02.020_bib20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1021\/bc0502614","article-title":"Improved biodistribution and radioimmunoimaging with poly(ethyleneglycol)-DOTA-conjugated anti-CEA diabody","volume":"17","author":"Li","year":"2006","journal-title":"Bioconjugate Chem."},{"key":"10.1016\/j.canlet.2010.02.020_bib21","doi-asserted-by":"crossref","first-page":"7981","DOI":"10.1158\/1078-0432.CCR-08-0324","article-title":"High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy","volume":"14","author":"Zhang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib22","first-page":"136","article-title":"Isolation and characterization of human lung cancer cell subline with different metastatic potential","volume":"24","author":"Zhu","year":"1995","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"key":"10.1016\/j.canlet.2010.02.020_bib23","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-08-0233","article-title":"TMTPI, a novel tumor-homing peptide specifically targeting metastasis","volume":"14","author":"Yang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib24","doi-asserted-by":"crossref","first-page":"6432","DOI":"10.1158\/1078-0432.CCR-07-4401","article-title":"Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22 small interfering RNA on human lung cancer xenografts","volume":"14","author":"Zhang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/CAD.0b013e3280112779","article-title":"An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity","volume":"18","author":"Miao","year":"2007","journal-title":"Anti-Cancer Drugs"},{"key":"10.1016\/j.canlet.2010.02.020_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-1759(98)00127-6","article-title":"Highly efficient recovery of functional single-chain Fv fragments from inclusion bodies overexpressed in Escherichia coli by controlled introduction of oxidizing reagent\u2014application to a human single-chain Fv fragment","volume":"219","author":"Tsumoto","year":"1998","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.canlet.2010.02.020_bib27","first-page":"724","article-title":"Squalamine treatment of human tumors in nu\/nu mice enhances platinum-based chemotherapies","volume":"7","author":"Williams","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib28","first-page":"1574","article-title":"The new dioxolane, (\u2013)-2\u2032-deoxy-3\u2032-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts","volume":"6","author":"Weitman","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib29","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1158\/0008-5472.CAN-04-3197","article-title":"Broad-spectrumGproteincoupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer","volume":"65","author":"Guha","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10549-008-0043-0","article-title":"PE38KDEL-loaded anti-HER2 nanoparticles inhibit breast tumor progression with reduced toxicity and immunogenicity","volume":"115","author":"Gao","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.canlet.2010.02.020_bib31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1006\/jmbi.2001.4621","article-title":"Solution structures of C-1027 apoprotein and its complex with the aromatized chromophore","volume":"309","author":"Tanaka","year":"2001","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.canlet.2010.02.020_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10555-006-7886-9","article-title":"Matrix metalloproteinases and tumor metastasis","volume":"25","author":"Deryugina","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2010.02.020_bib33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/35077241","article-title":"The microenvironment of the tumour\u2013host interface","volume":"411","author":"Liotta","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2010.02.020_bib34","doi-asserted-by":"crossref","first-page":"11438","DOI":"10.1158\/0008-5472.CAN-07-1882","article-title":"Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma","volume":"67","author":"Melani","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib35","first-page":"1243","article-title":"Immunoscintigraphy of anti-type IV collagenase monoclonal antibody in nude mice bearing human lung cancer xenograft","volume":"22","author":"Dai","year":"2003","journal-title":"Ai Zheng"},{"key":"10.1016\/j.canlet.2010.02.020_bib36","doi-asserted-by":"crossref","first-page":"7896","DOI":"10.1021\/ja060724w","article-title":"Antitumor enediyne chromoprotein C-1027: mechanistic investigation of the chromophore-mediated self-decomposition pathway","volume":"128","author":"Inoue","year":"2006","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.canlet.2010.02.020_bib37","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1023\/A:1025785505977","article-title":"Drug delivery and transport to solid tumors","volume":"20","author":"Jang","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.canlet.2010.02.020_bib38","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1021\/cr010202t","article-title":"Protein ectodomain shedding","volume":"102","author":"Arribas","year":"2002","journal-title":"Chem. Rev."},{"key":"10.1016\/j.canlet.2010.02.020_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1515\/BC.2002.007","article-title":"Transmodulation of cell surface regulatory molecules via ectodomain shedding","volume":"383","author":"Dello Sbarba","year":"2002","journal-title":"Biol. Chem."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510001217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383510001217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T04:52:41Z","timestamp":1544590361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383510001217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0304383510001217"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2010.02.020","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}